At Sheba Medical Center, various departments including the Oral and Maxillofacial Institute, Ear, Nose and Throat Department, Institute of Pathology, and the Center for Cancer Research are collaborating on developing a saliva test for oral cavity cancer. This is the first target due to its direct contact with infected tissues and potential for early detection. The development of the Salignostix platform for saliva processing has already seen success in rapid tests for pregnancy, corona and more.
Dr. Alex Dobrian of Sheba Medical Center recognizes the impact of early detection on patient recovery, especially for head and neck cancers. This collaboration marks a shift for Salignostix from home tests to professional medical devices at hospitals. The ARC platform at Sheba Medical Center has been instrumental in this partnership by focusing on health innovation through global collaborations. The company was founded by researchers from Hebrew University and has developed rapid tests for various health conditions including respiratory infections and early pregnancy detection. By incorporating saliva-based tests into medical devices, this collaboration aims to revolutionize cancer diagnostics.
Salignostix is expanding its capabilities through this joint effort with Sheba Medical Center by integrating its technology into hospital devices. This advances its mission of providing innovative health solutions with support from leading doctors and researchers. With this collaboration having the potential to make significant strides in cancer detection and treatment, it highlights the importance of interdisciplinary teams working together towards a common goal in healthcare.
